Detection of glyco‐mucin profiles improves specificity of MUC16 and MUC1 biomarkers in ovarian serous tumours

Molecular Oncology - Tập 9 - Trang 503-512 - 2015
Sara Ricardo1, Lara Marcos-Silva1,2,3, Daniela Pereira1, Rita Pinto1, Raquel Almeida1,2,4, Ola Söderberg5, Ulla Mandel3, Henrik Clausen3, Ana Felix6,7, Nuno Lunet8,9, Leonor David1,2
1IPATIMUP, Institute of Molecular Pathology and Immunology of the University of Porto, Portugal
2Faculty of Medicine of The University of Porto, Porto, Portugal
3Copenhagen Center for Glycomics, Department of Cellular and Molecular Medicine and School of Dentistry, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark
4Department of Biology, Faculty of Sciences of the University of Porto, Porto, Portugal
5Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Biomedical Center, Uppsala University, Uppsala, Sweden
6Instituto Português de Oncologia de Lisboa, Lisboa, Portugal
7Faculdade de Ciências Médicas – CEDOC, Universidade Nova de Lisboa, Lisboa, Portugal
8Department of Clinical Epidemiology, Predictive Medicine and Public Health, Faculty of Medicine, University of Porto, Porto, Portugal
9Institute of Public Health – University of Porto (ISPUP), Porto, Portugal

Tóm tắt

The CA125 assay detects circulating MUC16 and is one of the most widely used cancer biomarkers for the follow‐up of ovarian cancer. We previously demonstrated that detection of aberrant cancer‐associated glycoforms of MUC16 as well as MUC1 in circulation could improve the yield of these serum assays. Our aim was to refine ovarian cancer biomarkers by detection of aberrant glycoforms (Tn, STn, and T) of MUC16 and MUC1 in ovarian cancer tissue using Proximity Ligation Assays (PLA).We studied two series of serous ovarian tumours, a pilot series of 66 ovarian tumours (27 cystadenomas, 16 borderline tumours and 23 adenocarcinomas) from Centro Hospitalar S. João, Porto and a validation series of 89 ovarian tumours (17 cystadenomas, 25 borderline tumours and 47 adenocarcinomas) from the Portuguese Institute of Oncology Francisco Gentil, Lisbon.PLA reactions for MUC16/Tn, MUC16/STn, MUC1/Tn and MUC1/STn were negative in benign lesions but often positive in borderline and malignant lesions, in both series. An even better yield was obtained based on positivity for any of the four glyco‐mucin profiles, further increasing sensitivity to 72% and 83% in the two series, respectively, with 100% specificity. The strategy is designated glyco‐mucin profiling and provides strong support for development of PLA‐based serum assays for early diagnosis.

Tài liệu tham khảo

10.1097/IGC.0b013e3182473292 10.1371/journal.pone.0095192 10.4103/0022-3859.40790 10.1067/S0002-9378(03)00579-9 10.1172/JCI110380 10.1155/2013/917898 10.1021/pr3010474 10.1093/glycob/cwp161 10.1158/1940-6207.CAPR-10-0195 10.1038/modpathol.2013.130 10.1074/mcp.M900248-MCP200 10.1053/hupa.2000.9776 10.1016/S1470-2045(13)70546-1 2012 International Agency for Research on Cancer Lyon France J. Ferlay I. Soerjomataram M. Ervik R. Dikshit S. Eser C. Mathers M. Rebelo D.M. Parkin D. Forman F. Bray Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 10.1038/nbt0502-473 10.1373/clinchem.2007.093195 10.1016/S0046-8177(97)90012-5 10.1016/j.tcb.2010.11.004 10.1016/S0014-4835(03)00204-5 10.1016/S1470-2045(07)70273-5 10.1073/pnas.0400552101 10.1371/journal.pone.0026839 10.1146/annurev.physiol.70.113006.100659 10.1093/jjco/hyp168 10.1093/jnci/djt439 10.1093/oxfordjournals.humrep.a136832 10.1158/1055-9965.EPI-13-1361 10.1155/2014/634289 Kjeldsen T., 1988, Preparation and characterization of monoclonal antibodies directed to the tumor-associated O-linked sialosyl-2–--6 alpha-N-acetylgalactosaminyl (sialosyl-Tn) epitope, Cancer Res, 48, 2214 10.1016/j.ygyno.2013.03.001 10.1074/jbc.M302741200 10.1021/ja410086d 10.1158/1940-6207.CAPR-11-0053 10.1111/1523-1747.ep12484064 10.1021/pr500215g Moore R.G., 2010, Comparison of a novel multiple marker assay vs the risk of malignancy index for the prediction of epithelial ovarian cancer in patients with a pelvic mass, Am. J. Obstet. Gynecol, 203, e221 10.1159/000217982 10.1111/j.1582-4934.2011.01436.x 10.1007/s00428-012-1203-5 10.1097/01.pgp.0000101080.35393.16 Simon R., 2004, Tissue microarrays, Methods Mol. Med, 97, 377 10.1016/S1470-2045(08)70277-8 10.1200/JCO.2004.03.091 10.1038/nmeth947 10.1038/emboj.2013.79 10.1016/j.ygyno.2014.01.005 10.1073/pnas.1019330108 10.1002/ijc.2910280104 10.1038/sj.bjc.6606092 10.1586/epr.10.10 10.1152/ajplung.1998.275.1.L172 10.1158/1940-6207.CAPR-10-0193
Thông tin
Thông tin xuất bản

Molecular Oncology

Tập 9

503-512

Thông tin tác giả